A Pilot Study Of Pirfenidone For The Treatment Of Radiation-Induced Fibrosis
- Determine the safety and therapeutic efficacy of pirfenidone in cancer patients with
OUTLINE: Patients receive oral pirfenidone 3 times daily. Treatment continues for up to 2
years in the absence of disease progression or unacceptable toxicity.
Principal functional abilities are assessed at baseline, every 3 months, and at termination
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued for this study within 1 year.
Primary Purpose: Supportive Care
Kevin Camphausen, MD
NCI - Radiation Oncology Branch; ROB
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|